Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

Dirk Schadendorf, Caroline Robert, John B.A.G. Haanen et al.|European Journal of Cancer|2017

Cited by 171